Urokinase-Derived Peptide A6

DCTPepD ID  DCTPepD0101

Active Ingredients   Urokinase-Derived Peptide A6

Description  An octapeptide (amino acids 136-143) derived from the proteolytic enzyme urokinase plasminogen activator (uPA), with potential antineoplastic activity. A6 is derived from the nonreceptor-binding domain and connecting region of urokinase. Administration of A6 inhibits the interaction of uPA with its receptor uPAR, and may inhibit endothelial cell motility and tumor cell invasion. uPA and uPAR promote extracellular matrix degradation and growth factor activation and correlate positively with angiogenesis, cancer cell invasion and metastasis.

Synonyms  A6; ACETYL-LYS-PRO-SER-SER-PRO-PRO-GLU-GLU-NH2; uPA-derived Peptide A6; urokinase plasminogen activator (uPA)-derived peptide A6; Urokinase-Derived Peptide A6

Disease  Ovarian epithelial cancer, Fallopian tube cancer, Primary peritoneal cancer.

Classification

  

Peptide and derivative Antiangiogenesis agent

Structure Information


Molecular Formula  Not available

Molecular Weight  Not available

Active Sequence  KPSSPPEE

Sequence Length  8

Modification  C-terminal Ac, N-terminal NH2

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  Not available

DrugBank Accession Number  Not available

NCI Thesaurus Code  C91709  

UNII  KM64V5W7RA   GSRS

CAS  220334-14-5



Drug approval


Drug indication
    Investigated for use/treatment in persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00939809 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Fallopian Tube Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Recurrent Ovarian Carcinoma; Undifferentiated Ovarian Carcinoma Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.